Literature DB >> 18064496

Treatment of catheter-related bacteremia with tissue plasminogen activator antibiotic locks.

Ali Mirza Onder1, Jayanthi Chandar, Nancy Simon, Marie Saint-Vil, Denise Francoeur, Obioma Nwobi, Carolyn Abitbol, Gaston Zilleruelo.   

Abstract

This retrospective study was completed to investigate the effectiveness of tissue plasminogen activator (TPA) antibiotic locks (ABL) along with systemic antibiotics (AB) to clear catheter-related bacteremia (CRB) in children on chronic hemodialysis. There were 76 CRBs in 37 children. CRBs were successfully cleared with AB/ABL in 63/76 (83%) cases. Ten of 76 (13%) CRBs were symptomatic at 48 h of treatment. These were seven polymicrobial, two gram-negative, and one Candida CRB. 13/76 (17%) episodes required catheter exchange, and all were wire-guided exchanges. TPA-ABL/AB cleared gram-positive and gram-negative CRBs significantly better than polymicrobial CRBs (p < 0.01). The infection-free survival and the rate of recurrence at 45 days was not statistically different between the TPA-ABL/AB group and the catheter-exchange group. If CRB was symptomatic at 48 h of treatment, recurrence at 6 weeks was more frequent with persistent use of TPA-ABL/AB (p < 0.05). There were no episodes of metastatic infections, catheter malfunction from occlusion, or catheter breakdown during the course of TPA-ABL treatments. In conclusion, TPA-ABL can be safely and effectively used in the management of CRB, increasing the probability of catheter survival and preserving the vascular access site. With the exception of polymicrobial CRB, there is no disadvantage in using TPA-ABL/AB over catheter exchange, as the infection-free survival and the rate of recurrence are comparable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18064496     DOI: 10.1007/s00467-007-0687-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  36 in total

1.  Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports).

Authors:  T U Anthony; L G Rubin
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Guidelines for the prevention of intravascular catheter-related infections.

Authors:  Naomi P O'grady; Mary Alexander; E Patchen Dellinger; Julie L Gerberding; Stephen O Heard; Dennis G Maki; Henry Masur; Rita D McCormick; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne Randolph; Robert A Weinstein
Journal:  Am J Infect Control       Date:  2002-12       Impact factor: 2.918

3.  Antimicrobial lock therapy for catheter-related bacteraemia among patients on maintenance haemodialysis.

Authors:  E Bailey; N Berry; J S Cheesbrough
Journal:  J Antimicrob Chemother       Date:  2002-10       Impact factor: 5.790

4.  Vancomycin and ceftazidime bioactivities persist for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections by using the antibiotic lock technique.

Authors:  Y Haimi-Cohen; N Husain; J Meenan; G Karayalcin; M Lehrer; L G Rubin
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement.

Authors:  I Raad; W Costerton; U Sabharwal; M Sacilowski; E Anaissie; G P Bodey
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

6.  Vascular access survival in children and young adults receiving long-term hemodialysis.

Authors:  Ian J Ramage; Alan Bailie; Kay S Tyerman; John H McColl; Stephen G Pollard; Maggie M Fitzpatrick
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

7.  Management of bacteremia associated with tunneled-cuffed hemodialysis catheters.

Authors:  G A Beathard
Journal:  J Am Soc Nephrol       Date:  1999-05       Impact factor: 10.121

8.  Experience with autogenous arteriovenous access for hemodialysis in children and adolescents.

Authors:  Wayne S Gradman; Gary Lerner; Mark Mentser; Hector Rodriguez; Elaine S Kamil
Journal:  Ann Vasc Surg       Date:  2005-09       Impact factor: 1.466

9.  Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study.

Authors:  Nuria Fernandez-Hidalgo; Benito Almirante; Raquel Calleja; Isabel Ruiz; Ana M Planes; Dolors Rodriguez; Carles Pigrau; Albert Pahissa
Journal:  J Antimicrob Chemother       Date:  2006-04-05       Impact factor: 5.790

Review 10.  Microsurgery in children for creation of arteriovenous fistulas in renal and non-renal diseases.

Authors:  Pierre Bourquelot; Fabien Raynaud; Nicola Pirozzi
Journal:  Ther Apher Dial       Date:  2003-12       Impact factor: 1.762

View more
  3 in total

1.  Low infection rates and prolonged survival times of hemodialysis catheters in infants and children.

Authors:  Israel Eisenstein; Mahdi Tarabeih; Daniella Magen; Shirley Pollack; Imad Kassis; Amos Ofer; Ahuva Engel; Israel Zelikovic
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-02       Impact factor: 8.237

2.  A review of evolving dialysis catheter technologies.

Authors:  Martha-Grace Knuttinen; Sonia Bobra; Julian Hardman; Ron C Gaba; James T Bui; Charles A Owens
Journal:  Semin Intervent Radiol       Date:  2009-06       Impact factor: 1.513

3.  Prevention of catheter-related bacteremia in children on hemodialysis: time for action.

Authors:  Constantinos J Stefanidis
Journal:  Pediatr Nephrol       Date:  2009-07-23       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.